Important Notice

Not an Offer for Securities

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of the Company and conduct its own investigations and analysis.

Information is a Synopsis Only

This presentation only contains a synopsis of information on the Company and, accordingly, no reliance may be placed for any purpose whatsoever on the sufficiency or completeness of such information. Information presented in this presentation is subject to change without notice and REVA does not have any responsibility or obligation to inform you of any matter arising or coming to their notice after the date of this presentation, which may affect any matter in the presentation.

Forward-Looking Statements

This presentation contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding our plans to commence commercial operations and sell products, conduct clinical trials, develop pipeline products, incur losses from operations, list our securities for sale on a U.S. stock exchange, and assess and obtain future financings for operating and capital requirements. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the “Risk Factors” section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 7, 2018, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this presentation speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Disclaimer

This presentation and any supplemental materials have been prepared by the Company based on available information. The information contained in this presentation is an overview and does not contain all information necessary to make an investment decision. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of the Company, or any of its members, directors, officers, employees, or agents or advisers, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of the Company or any of its directors, officers, employees, or agents.

Fantom, Fantom Encore, Tyrocore, and MOTIV are trademarks of REVA Medical, Inc.
REVA Medical is a leader in bioresorbable polymer technologies for vascular applications

Commercializing proprietary products for Coronary Artery Disease and Peripheral Artery Disease and pursuing Embolization Therapies
~$14 Billion Market Opportunity in Vascular Applications

<table>
<thead>
<tr>
<th>Coronary Artery Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>• ~$4 billion global stent market</td>
</tr>
<tr>
<td>• CAD is the most common type of heart disease</td>
</tr>
<tr>
<td>• Occurs when a build-up of plaque blocks blood flow to the heart</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peripheral Artery Disease: Below-the-Knee</th>
</tr>
</thead>
<tbody>
<tr>
<td>• $3.2 billion global market potential</td>
</tr>
<tr>
<td>• Common in diabetic patients</td>
</tr>
<tr>
<td>• Occurs when a build-up of plaque blocks blood flow to the foot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Embolization Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• $1.3 billion global market potential</td>
</tr>
<tr>
<td>• Used to treat cancerous and non-cancerous tumors and to stop bleeding</td>
</tr>
<tr>
<td>• Purpose is to occlude blood vessels to restrict blood flow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peripheral Artery Disease: Above-the-Knee</th>
</tr>
</thead>
<tbody>
<tr>
<td>• $5.8 billion global market potential</td>
</tr>
<tr>
<td>• Symptomatic of advanced vascular disease</td>
</tr>
<tr>
<td>• Occurs when a build-up of plaque blocks blood flow to the leg</td>
</tr>
</tbody>
</table>

REVA’s Disruptive Technology: Tyrocore™

The World’s Only Radiopaque, Bioresorbable Polymer Approved for Use¹ in Medical Devices

Tyrocore Properties

• Proprietary bioresorbable polymer
• Strong for excellent mechanical properties
• X-ray visible, ideal for vascular procedures
• Naturally biocompatible: derived from the tyrosine amino acid
• Polymer properties are tailorable to meet a clinical application by modifying:
  – Strength
  – Flexibility
  – Degradation time
  – Drug delivery profile

¹ CE Mark Approved in Europe
# REVA’s Product Portfolio

## Built from Tyrocore

<table>
<thead>
<tr>
<th>Disease</th>
<th>Product</th>
<th>Regulatory Status</th>
<th>Commercial Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coronary Artery Disease</strong></td>
<td>Fantom® and Fantom Encore™ Bioresorbable Scaffolds</td>
<td>CE Mark</td>
<td>Available in Europe and Middle East</td>
</tr>
<tr>
<td><strong>Peripheral Artery Disease: Below-the-Knee</strong></td>
<td>MOTIV™ Bioresorbable Scaffolds</td>
<td>CE Mark</td>
<td>Limited Launch in Europe</td>
</tr>
<tr>
<td><strong>Peripheral Artery Disease: Above-the-Knee</strong></td>
<td>Bioresorbable scaffold</td>
<td>Pre-approval</td>
<td>R&amp;D</td>
</tr>
<tr>
<td><strong>Embolization Therapy</strong></td>
<td>Bioresorbable microbeads</td>
<td>Pre-approval</td>
<td>Prototype and Pre-clinical Feasibility</td>
</tr>
</tbody>
</table>
Coronary Program
BRS are Designed to Improve Long-Term Outcomes Compared to Metal DES

New-Generation DES Continue to Accruce Adverse Events through 10-Year Follow-up

ISAR-TEST 4 Study¹

BRS Function

Support Vessel Healing  Safely Resorb  Device-Free Vessel

3.3% per year increase in MACE with DES²

BRS are designed to resorb and eliminate risk of device-related adverse events

1) Kufner S, et al. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease Results From the ISAR-TEST 4 Randomized Trial. Circulation 2018;138:00–00 DOI: 10.1161/CIRCULATIONAHA.118.038065. 2) Bangalore, S. The Elusive Late Benefit of Biodegradable Polymer Drug Eluting Stents. Circulation 2018;DOI: 10.1161/CIRCULATIONAHA.118.038378.
REVA Has Demonstrated Excellent Clinical Performance with Fantom

<table>
<thead>
<tr>
<th>Product</th>
<th>2-Year Target Lesion Failure (TLF*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fantom II 1</td>
<td>4.6%</td>
</tr>
<tr>
<td>Absorb III 2</td>
<td>11.0%</td>
</tr>
<tr>
<td>Magmaris BIOSOLVE II &amp; III 3</td>
<td>5.5%</td>
</tr>
<tr>
<td>Xience ABSORB III 2</td>
<td>7.9%</td>
</tr>
<tr>
<td>Xience SPIRIT IV 4</td>
<td>6.9%</td>
</tr>
<tr>
<td>Resolute RESOLUTE US 5</td>
<td>7.3%</td>
</tr>
</tbody>
</table>

*TLF = cardiac death + target vessel MI + target lesion revascularization. The FANTOM II primary endpoint was Major Adverse Cardiac Events (MACE) = cardiac death + all MI + target lesion revascularization. The 24-month MACE rate was 5.0%.

---

Fantom Has Also Demonstrated Low Scaffold Thrombosis

Strong Performance through 2 Years

<table>
<thead>
<tr>
<th>Study</th>
<th>Fantom (n=240)</th>
<th>Absorb (n=1,322)</th>
<th>Xience DES (n=686)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scaffold Thrombosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute (0 to 1 day)</strong></td>
<td>0%</td>
<td>0.15%²</td>
<td>0.58%²</td>
</tr>
<tr>
<td><strong>Subacute (2 to 30 days)</strong></td>
<td>0.4%</td>
<td>0.91%²</td>
<td>0.15%²</td>
</tr>
<tr>
<td><strong>Late/Very Late (&gt;31 days)</strong></td>
<td>0.4%</td>
<td>0.76%²,³</td>
<td>0%²,³</td>
</tr>
</tbody>
</table>

REVA Has Launched Its 3rd Generation: Fantom Encore

Our Tyrocore Polymer Makes Fantom Encore the Most Advanced BRS

- **Thinnest strut profile** of any commercial, CE Mark BRS for deliverability and vessel healing

<table>
<thead>
<tr>
<th>Diameter</th>
<th>X-ray Visibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>95 μm</td>
<td>2.5 mm diameter</td>
</tr>
<tr>
<td>105 μm</td>
<td>3.0 mm diameter</td>
</tr>
<tr>
<td>115 μm</td>
<td>3.5 mm diameter</td>
</tr>
</tbody>
</table>

- **X-ray visible** for treatment accuracy
- **Key ease-of-use** features like single-step inflation and higher expansion range
- **Biocompatible** for safety
- **Stable** for room temperature shipping and storage
But Absorb Has Created Significant Headwinds and Changed The Competitive Landscape

Impact on BRS Market

- Competitors with PLLA scaffolds like Absorb gone from European market
- Chinese and Indian competitors with PLLA scaffolds focused on Chinese market with no plans to enter Europe
- Single remaining European competitor with magnesium-based scaffold is redesigning their product and postponing investment in randomized clinical trials

Fortunately, Absorb is Beginning to Demonstrate the Value of Bioresorption

**Target Lesion Failure**

**Landmark Analysis**

- **Absorb**
- **XIENCE**

0-36 Months:
- HR [95% CI] = 1.31 [0.99, 1.72]
- *p* = 0.05

36-49 Months:
- HR [95% CI] = 1.21 [0.68, 2.18]
- *p* = 0.51

**Absorb and Xience Show Equivalent Performance between 3 & 4 Years**

Note: 4-year window includes follow-up through 49 months.

**REVA’s Coronary Program Status**

**Commercial Results: Progress Every Quarter**

<table>
<thead>
<tr>
<th>Targeted Launch</th>
<th>Q3 2017</th>
<th>Q4 2017</th>
<th>Q1 2018</th>
<th>Q2 2018</th>
<th>Q3 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct Sales</strong> in Germany, Switzerland, and Austria</td>
<td><strong>Distributor:</strong> Turkey</td>
<td><strong>Direct:</strong> Belgium and Netherlands</td>
<td><strong>Distributor:</strong> Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Customers</strong></td>
<td>125% increase</td>
<td>78% increase</td>
<td>38% increase</td>
<td>18% increase</td>
<td></td>
</tr>
<tr>
<td><strong>Billings</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>$105,000</td>
<td>$98,000</td>
<td>$128,000</td>
<td>$149,000</td>
<td>$185,000</td>
</tr>
<tr>
<td><strong>Revenue</strong>&lt;sup&gt;2&lt;/sup&gt;</td>
<td>$17,000</td>
<td>$28,000</td>
<td>$53,000</td>
<td>$91,000</td>
<td>$93,000</td>
</tr>
</tbody>
</table>

With very few competitors remaining in BRS and an advanced 3<sup>rd</sup> generation product, REVA is positioned to win in coronary; however, we now need to drive a change to the ESC Guidelines. Next steps:

- Conduct our 1,500 patient post-market trial*
- Launch our post-market randomized clinical trial in 2019*
- Continue to publish clinical data (3-year results in May 2019 at EuroPCR)

* Product to be purchased commercially for the trial.

1) Product billings are invoiced at the time of shipment. 2) Revenue is recognized per our policy outlined in Form 10-Q filed with the US Securities and Exchange Commission (the “SEC”) on November 6, 2018.
Building Clinical Evidence to Change the ESC Guidelines and Drive Commercial Use

### Pre-Market Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>FANTOM I</td>
<td>First-in-human safety study (n=7)</td>
<td>Year 4</td>
</tr>
<tr>
<td>FANTOM II Cohorts A&amp;B</td>
<td>Multi-center safety and performance study (n=240)</td>
<td>Year 3</td>
</tr>
<tr>
<td>FANTOM II Cohort C</td>
<td>Long lesion and multiple vessel study (n=33)</td>
<td>Year 1</td>
</tr>
<tr>
<td>FANTOM STEMI</td>
<td>Single center pilot study in STEMI (n=20)</td>
<td></td>
</tr>
</tbody>
</table>

### Post-Market Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>FANTOM Post Market Trial</td>
<td>Multi-center post-market trial (n=1,500)</td>
<td>enrolling</td>
</tr>
<tr>
<td>FANTOM III</td>
<td>Multi-center RCT vs. metallic DES (n~1,800)</td>
<td>planning</td>
</tr>
</tbody>
</table>
REVA’s Shift in Business Strategy

• In coronary we will focus in Europe on commercial growth and driving change to the ESC Guidelines

• Our broader business strategy has shifted to:
  • Right-sized operations for slower projected coronary growth
  • Increased focus on peripheral and embolization therapy programs with nearer term value creation opportunities
Peripheral Program
Peripheral Artery Disease of the Lower Limbs

Below-the-Knee (BTK)
• Common indication is critical limb ischemia
• Patients have reduced blood flow leading to wounds, infections, and amputation
• Critical limb ischemia (CLI) is a heart attack for the leg
  — 25% of CLI patients have amputation within one year\(^1\)
  — 25% of CLI patients die within one year\(^1\)

Above-the-Knee (ATK)
• Common indication is intermittent claudication
• Patients have reduced blood flow causing severe pain and reduced function

## Current Treatment Options

Revascularization Improves Outcomes but there are Limitations with Current Treatment Options

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Benefit</th>
<th>Challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balloon angioplasty (PTA)</strong></td>
<td>• Restores blood flow to the vessel</td>
<td>• High rates of restenosis</td>
</tr>
<tr>
<td><strong>Drug-coated balloons (DCB)</strong></td>
<td>• Restores blood flow to the vessel</td>
<td>• Lacks mechanical support and sustained drug delivery during vessel healing</td>
</tr>
<tr>
<td></td>
<td>• Delivers drug to reduce tissue growth during initial vessel healing</td>
<td></td>
</tr>
<tr>
<td><strong>Drug-eluting stents (DES)</strong></td>
<td>• Restores blood flow to the vessel</td>
<td>• Challenges with stent fracture</td>
</tr>
<tr>
<td></td>
<td>• Mechanical support to vessel</td>
<td>• Interferes with retreatment</td>
</tr>
<tr>
<td></td>
<td>• Sustained drug delivery during vessel healing</td>
<td></td>
</tr>
</tbody>
</table>
Bioresorbable Scaffolds May Improve Treatment for Patients with PAD

Value of BRS:

- Provide mechanical support and sustained drug delivery during vessel healing
- Eliminate issues associated with metal fracture
- Preserve retreatment options
BRS Shown to Help Patients with PAD

Below-the-Knee

- Abbott’s Absorb scaffold in BTK\(^1\):
  - 33 patients with critical limb ischemia treated with Absorb
  - 100% of critical limb ischemia patients avoided amputation at 1 year
- Meril’s Credence scaffold in BTK\(^2\):
  - 30 patients with critical limb ischemia treated with Credence
  - 97% of patients avoided amputation at 6 months
- Results compare favorably to 25% 1-year limb amputation rate with conventional treatment\(^3\)

Above-the-Knee

- Abbott’s Esprit scaffold in ATK\(^4\):
  - 35 patients intermittent claudication patients treated with Esprit
  - 2-Year target lesion revascularization range of 11.8% compares favorably to
    - DES: 19.5% with paclitaxel-eluting Zilver stent
    - DCB: 30% with paclitaxel-eluting Lutonix DCB

---

REVA’s MOTIV BTK Bioresorbable Scaffold

1st & Only BRS Approved for Below-the-Knee Revascularization Therapy

- **CE Mark** secured in July 2018
- Made with Tyrocore
- **Thin strut profile** for deliverability and vessel healing
- **X-ray visible** for treatment accuracy
- **Strong** for vessel support
- **Sustained drug delivery** to maintain vessel patency
Peripheral Milestones

• Limited launch of MOTIV in Europe, Q1 2019
• Evaluating pathways for geographic expansion
• Polymer R&D for optimal characteristics of scaffolds for ATK applications
• Development of tailored bioresorbable scaffolds for peripheral artery disease applications
Embolization Therapy Program
Embolization Therapy is an Established Procedure

Embolization Overview

- Purpose to occlude blood vessels to restrict blood flow:
  - Restrict blood flow to a tumor in order to shrink the tumor
  - Stop wound bleeding
- Minimally invasive procedures
  - Microbeads are delivered through catheters guided by x-ray in a cath lab

Current Applications

- Cancerous tumors (oncology)
  - Hepatocellular carcinoma (liver cancer)
  - Renal cell carcinoma (kidney cancer)
- Non-cancerous tumors (gynecology and proctology)
  - Uterine fibroids in women
  - Benign prostatic hyperplasia in men
- Stop bleeding
  - Ulcerations and other wounds in the gastrointestinal tract
  - Hemorrhage or vascular injury
REVA’s Technology Fills an Unmet Need

REVA Has the Only X-ray Visible and Bioresorbable Embolic Microbead

- X-Ray Visible
  - BTG
  - Opportunity for REVA

- Not Visible Under X-Ray
  - BTG
  - Boston Scientific
  - MERITMEDICAL
  - TERUMO
  - COOK MEDICAL
  - SIRTeX
  - Medtronic

- Permanent
- Absorbable
REVA’s Bioresorbable Embolic Microbeads

REVA’s Polymer Technology Meets All Requirements of the Ideal Embolization Particle

- **X-ray visible** for treatment accuracy
- **Compressible and buoyant** for ease-of-use and injectability
- **Biocompatible** for safety
- **Loadable** for drug delivery
- **Resorbable** to avoid chronic inflammation and allow retreatment
Safety and Efficacy Demonstrated in Pre-Clinical Study

- Renal embolization in swine model
- Size reduction of treated tissue observed in all animals
- No evidence of thrombosis, hemorrhage, or inflammation

Embolization Therapy Milestones

• Final design selection
• Manufacturing scale-up
• Product validation testing
• Regulatory filing:
  – US 510k
  – CE Mark design dossier
• Indication expansion studies
• Conduct early feasibility studies of small molecule and large molecule drug-loaded microbeads targeting oncology
Innovating to Build a $1+ Billion Company

Coronary Revenue Potential

Peripheral and Embolics Market Opportunities

$9.0+ BILLION

BELOW- AND ABOVE-THE-KNEE

U.S.: 19%
China: 59%
Europe: 15%
Japan: 7%

$1.3+ BILLION

EMBOLIZATION THERAPY

Asia: 39%
U.S.: 33%
Europe: 28%

Cumulative revenue potential with new market entry:

Europe Direct $140
Europe Distributor $220
ME & Asia Distributor $292
All CE Mark $520
Japan $590
US $850
China $1,210

Revenue calculation assumes 20% market share and $1,000 ASP

Experienced Management Team

Jeffrey Anderson
PRESIDENT

Leigh Elkolli
CHIEF FINANCIAL OFFICER

Jessica Earley
VP, OPERATIONS AND PRODUCT DEVELOPMENT
Board of Directors

Ray Larkin, Chairman (2017– )
Eunoe Inc, Bentley Labs, Nellcor Puritan Bennett

Bob Stockman, Co-Founder (1999– )
Ioptex, “A” Company, Critikon

Brian Dovey (2001– )
Domain Associates, Rorer Group

Robert Thomas (2010– )
Citigroup Australia, multiple boards

Ross Breckenridge, MA FRCP PhD (2015– )
Silver Creek Pharmaceuticals, University College London Hospital
# REVA Investment Highlights

## Disruptive Technology
- Proprietary x-ray visible, bioresorbable polymer technologies for vascular applications
- Strong IP patent protection extending 2029-2034

## Large, Profitable Markets
- $4 billion coronary stent market ripe for innovation
- $9.0 billion market opportunity for BRS to treat below- and above-the-knee peripheral artery disease
- $1.3 billion market opportunity for embolization therapy in oncology and other tumors

## Commercializing Fantom Encore
- Commercial: Germany, Switzerland, Austria, Turkey, Italy, Netherlands, Belgium, and Luxembourg
- In progress: Additional countries in Europe, Middle East, and Asia

## Launching in Peripheral Market
- Limited launch of MOTIV in 2019 in select centers
- Evaluating pathways for expansion in Asia and US
- Developing crush recoverable polymer for above-the-knee peripheral artery disease

## Corporate Facts
- Listed on Australian securities exchange in 2010 (ASX: RVA.AX)
- Cash: $7.1 million\(^1\)
- Mkt Cap: $73 million\(^2\)
- SEC registered

---

1. Includes cash, as of September 30, 2018.
Fantom, Fantom Encore, and MOTIV have CE Mark only. Fantom, Fantom Encore, and MOTIV are available in select countries in Europe and the Middle East. Fantom, Fantom Encore, and MOTIV not available in the U.S. or other countries that do not accept CE Mark. Fantom, Fantom Encore, MOTIV, and Tyrocore are trademarks of REVA Medical, Inc.